Lori Farrar
National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

6th January 2015

RE: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia [ID650]

Dear Lori,

Thank you for providing the opportunity to comment on the ACD for the above appraisal.

We are pleased that the Committee has chosen to issue positive guidance for the sub group of patients that are unsuitable for bendamustine. If converted to final guidance this will allow people with chronic lymphocytic leukaemia to benefit from the significant survival advantage that obinutuzumab offers over existing treatment.

I would also like to extend my thanks for identifying an earlier Committee meeting for development of the FAD, which could provide patients access to this important drug by the end of May.

We would be happy to provide any additional information that is needed by the Committee to conclude this appraisal.

Kind Regards,

[redacted]

[redacted]

[redacted] [redacted]

Roche Products Limited
6 Falcon Way
Shire Park
Welwyn Garden City
Herts AL7 1TW
Registered No. 100674

Health Economics and Strategic Pricing

Tel. +44 (0) 1707 360000
Fax +44 (0) 1707 384527